1-3 of 3
Michael Copeman
Close
Sort by
Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS
Journal: Blood
Blood (2007) 110 (11): 1167.
https://doi.org/10.1182/blood.V110.11.1167.1167
Published: 2007
Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg
Journal: Blood
Blood (2005) 106 (11): 164.
https://doi.org/10.1182/blood.V106.11.164.164
Published: 2005
Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP
Journal: Blood
Blood (2004) 104 (11): 1020.
https://doi.org/10.1182/blood.V104.11.1020.1020
Published: 2004